Abstract
Purpose
Breast cancer is the most common malignancy among young women of reproductive age. Adjuvant treatment with tamoxifen reduces the risk of recurrence in hormone-sensitive breast cancer. However, the use of tamoxifen is considered contraindicated during pregnancy, because of a limited number of case reports demonstrating potential adverse effects on the fetus. The objective of this report is to give a more broad overview of the available data on the effect of tamoxifen exposure during pregnancy.
Methods
A literature review was performed using PubMed and the databases of the Netherlands Pharmacovigilance Centre Lareb and of the International Network on Cancer, Infertility, and Pregnancy.
Results
A total of 238 cases of tamoxifen use during pregnancy were found. Of the 167 pregnancies with known outcome, 21 were complicated by an abnormal fetal development. The malformations described were non-specific and the majority of cases concerned healthy infants despite exposure to tamoxifen.
Conclusion
There seems to be an increased risk of fetal abnormalities when taking tamoxifen during pregnancy (12.6% in contrast to 3.9% in the general population), but the evidence is limited and no causal relationship could be established. The possible disadvantage of postponing or discontinuing tamoxifen for the maternal prognosis is unclear. Patients should be counseled about the use of tamoxifen during pregnancy instead of presenting it as being absolutely contraindicated.
Similar content being viewed by others
References
The Netherlands Cancer Registry, the Netherlands Comprehensive Cancer Organisation (IKNL). https://www.cijfersoverkanker.nl/home-36.html. Accessed 15 Oct 2018
Breast Cancer, Dutch National Guideline, IKNL, version 1.0 (2018) https://richtlijnendatabase.nl/en/richtlijn/breast_cancer/breast_cancer.html. Accessed 15 Oct 2018
EBCTCG, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet 378(9793):771–784
Barthelmes L, Gateley CA (2004) Tamoxifen and pregnancy. Breast 13(6):446–451
Faddy MJ (2000) Follicle dynamics during ovarian ageing. Mol Cell Endocrinol 163(1–2):43–48
Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N (1999) Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17(8):2365–2370
Berger JC, Clericuzio CL (2008) Pierre Robin sequence associated with first trimester fetal tamoxifen exposure. Am J Med Genet A 146(16):2141–2144
Cullins SL, Pridjian G, Sutherland CM (1994) Goldenhar’s syndrome associated with tamoxifen given to the mother during gestation. JAMA 271(24):1905–1906
Tewari K, Bonebrake RG, Asrat T, Shanberg AM (1997) Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet 350(9072):183
Osborne CK (1998) Drug therapy: tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–1618
Scripture CD, Sparreboom A, Figg WD (2005) Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 6:780–789
Ruiz-Velasco V, Rosas-Arceo J, Matute MM (1979) Chemical inducers of ovulation: comparative results. Int J Fertil 24:61–64
Tsuiki A, Uehara S, Kyono K, Saito A, Hoshi K, Hoshiai H et al (1984) Induction of ovulation with an estrogen antagonist, tamoxifen. Tohoku J Exp Med 144:21–31
Suginami H, Yano K, Kitagawa H, Matsubara K, Nakahashi N (1993) A clomiphene citrate and tamoxifen citrate combination therapy: a novel therapy for ovulation induction. Fertil Steril 59:976–979
Regon L, Braude PR, Trembath P (1989) Influence of past reproductive performance on risk of spontaneous abortion. Br Med J 299:541–545
Jain JK, Meckstroth KR, Park M, Mishell DR Jr (1999) A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. Contraception 60(6):353–356
Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M et al (2005) Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: Implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56(suppl 1):10–20
Jyoti B, Bharat C, Ankita N, Munita B, Sudeep G (2016) Pregnancy on tamoxifen: case-report and review of literature. South Asian J Cancer 5(4):209–210
Colleoni M, Munzone E (2015) Navigating the challenges of endocrine treatments in premenopausal women with ER-positive early breast cancer. Drugs 75(12):1311–1321
Braems G, Denys H, De Wever O, Cocquyt V, Van de Broecke R (2011) Use of tamoxifen before and during pregnancy. Oncologist 16(11):1547–1551
Zhou MH, Han GZ, Chu YH (1991) Effects of antiestrogenic drug tamoxifen on human placental secretion of progesterone and human chorionic gonadotropin during early gestation. Yao Xue Xue Bao 26(11):801–804
Furukawa S, Hayashi S, Usuda K, Abe M, Ogawa I (2012) The impairment of metrial gland development in tamoxifen exposed rats. Exp Toxicol Path 64:121–126
Isaacs RJ, Hunter W, Clark K (2001) Tamoxifen as systemic treatment of advanced breast cancer during pregnancy-case report and literature review. Gynecol Oncol 80(3):405–408
Weiss G (2000) Endocrinology of parturition. J Clin Endocrinol Metab 85(12):4421–4425
Product information. Nolvadex. Zeneca Pharmaceuticals (1997)
Furr BJ, Valcaccia B, Challis JR (1976) The effects of Nolvadex (tamoxifen citrate: ICI 46,474) on pregnancy in rabbits. J Reprod Fertil 48:367–369
Clark JH, McCormack SA (1980) The effect of clomid and other triphenylethylene derivatives during pregnancy and the neonatal period. J Steroid Biochem 12:47–53
Pasqualini JR, Gulino A, Sumida C, Screpanti I (1984) Anti-estrogens in fetal and newborn target tissues. J Steroid Biochem 20:121–128
Gulino A, Screpanti I, Pasqualini JR (1984) Differential estrogen and antiestrogen responsiveness of the uterus during development in the fetal, neonatal and immature guinea pig. Biol Reprod 31:371–381
Nguyen BL, Giambiagi N, Mayrand C, Lecerf F, Pasqualini JR (1986) Estrogen and progesterone receptors in the fetal and newborn vagina of guinea pig: biological, morphological, and ultrastructural responses to tamoxifen and estradiol. Endocrinology 119:978–988
Pasqualini JR, Giambiagi N, Sumida C, Nguyen BL, Gelly C, Mayrand C et al (1986) Biological responses of tamoxifen in the fetal and newborn vagina and uterus of the guinea-pig and in the R-27 mammary cancer cell line. J Steroid Biochem 24:99–108
Hines M, Alsum P, Roy M, Gorski RA, Goy RW (1987) Estrogenic contributions to sexual differentiation in the female guinea pig: influences of diethylstilbestrol and tamoxifen on neural, behavioral, and ovarian development. Horm Behav 21:402–417
Cunha GR, Taguchi O, Namikawa R, Nishizuka Y, Robboy SJ (1987) Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract. Hum Pathol 18:1132–1143
Chamness GC, Bannayan GA, Landry LA Jr, Sheridan PJ, McGuire WL (1979) Abnormal reproductive development in rats after neonatally administered antiestrogen (tamoxifen). Biol Reprod 21:1087–1090
Iguchi T, Hirokawa M, Takasugi N (1986) Occurrence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen. Toxicology 42:1–11
Harper MJK (1992) Agents with antifertility effects during preimplantation stages of pregnancy. In: Moghissi KS, Hafez ESE (eds) Biology of mammalian fertilization and implantation. Charles C. Thomas, Springfield, pp 431–492
Furr BJA, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127–205
Grandvuillemin A, Rousseau T, Laurent N, Meyer F, Lebouvier M, Disson-Dautriche A (2009) A case of sexual ambiguity under tamoxifen during pregnancy. Fund Clin Pharmacol 23(Suppl 1):37
Koca T, Akgun Z, Yucel SB, Dag NZ, Teomete M (2011) Pregnancy a short time after multimodal therapy for bilateral breast cancer: a case report and review of literature. J Oncol Pharm Pract 17(4):440–443
Koca E, Kuzan TY, Babacan T, Turkbeyler IH, Furkan S, Altundag K (2013) Safety of tamoxifen during pregnancy: 3 case reports and review of the literature. Breast Care (Basel) 8(6):453–454
Oksuzoglu B, Güler N (2002) An infertile patient with breast cancer who delivered a healthy child under adjuvant tamoxifen therapy. Eur J Obstet Gynecol Reprod Biol 104(1):79
Koizumi K, Aono T (1986) Pregnancy after combined treatment with bromocriptine and tamoxifen in two patients with pituitary prolactinomas. Fertil Steril 46(2):312–314
Ishizuka S, Satou S (2016) A case of delivery of healthy infant in breast cancer patient incidentally treated with goserelin acetate and tamoxifen during pregnancy. Breast Cancer 23(1):164–166
Andreadis C, Charalampidou M, Diamantopoulos N, Chouchos N, Mouratidou D (2004) Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer. Gynecol Oncol 95(1):252–255
Clark S (1993) Prophylactic tamoxifen. Lancet 342:168
Schönbeck U, Hindori-Mohangoo AD, Masurel N, Van der Pal-de Bruin KM (2015) TNO report: Congenital malformations in the Netherlands 2001–2013: Based on Netherlands Perinatal Registry. https://repository.tudelft.nl/view/tno/uuid%3A1879cf51-0f9e-4051-8829-296fdcad2847. Accessed 20 Dec 2018
Nye L, Rademaker A, Gradishar WJ (2017) Breast cancer outcomes after diagnosis of hormone-positive breast cancer and subsequent pregnancy in the Tamoxifen Era. Clin Breat Cancer 17(4):e185–e189
Hershman DL, Shao T, Kushi LH, Buono D, Yann Tsai W, Fehrenbacher L, Kwan M, Lin Gomez S, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537
Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer (POSITVE). http://clinicaltrials.gov/ct2/show/NCT02308085. Accessed 15 Oct 2018
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
Not applicable.
Rights and permissions
About this article
Cite this article
Schuurman, T.N., Witteveen, P.O., van der Wall, E. et al. Tamoxifen and pregnancy: an absolute contraindication?. Breast Cancer Res Treat 175, 17–25 (2019). https://doi.org/10.1007/s10549-019-05154-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-019-05154-7